Controversy surrounding psychiatry

Freeing the mad from chains
"The Extraction of the Stone of Madness". Art between 1488 and 1516
Pieter Huys: A surgeon extracting the stone of folly
Pieter Jansz. Quast,
Die Steinoperation, ca 1630

Controversy has often surrounded psychiatry.[1] Psychiatric treatments are sometimes seen to be ultimately more damaging than helpful to patients. Psychiatry is often thought to be a benign medical practice, but at times is seen by some as a coercive instrument of oppression. Psychiatry is seen to involve an unequal power relationship between doctor and patient, and critics of psychiatry claim a subjective diagnostic process, leaving much room for opinions and interpretations. In 2013, psychiatrist Allen Frances said that "psychiatric diagnosis still relies exclusively on fallible subjective judgments rather than objective biological tests".[1][2][3][4] Every society, including liberal Western society, permits compulsory treatment of mental patients.[1]

Psychiatry's history involves what some view as dangerous treatments.[1] Electroconvulsive therapy is one of these, which was used widely between the 1930s and 1960s and is still in use today. The brain surgery procedure lobotomy is another practice that was ultimately seen as too invasive and brutal.[4] The term anti-psychiatry was coined by psychiatrist David Cooper in 1967 and is understood in current psychiatry to mean opposition to psychiatry's perceived role in many aspects of treatment.[1]

Background

Too often it is felt institutions have too much power, concerns of patients or their relatives are ignored.[5] Psychiatric nurses impose decisions, are reluctant to share information and feel they know best. Only a minority of staff involve patients in decision making.[6] Client empowerment can improve power imbalance. Psychiatrically ill patients are at risk of abuse and discrimination in the mental health system and also the primary care sector. Studies are needed to determine whether power imbalance leads to abuse.[7] Some degree of power imbalance appears inevitable since some patients lack decision making capacity but even then patients benefit from being impowered within their limits. For example, a patient felt lethargic in mornings due to medication she was required to take. She was allowed to stay in bed and miss breakfast as she wanted.[8] Multidisciplinary teams benefit patients to the extent that professionals with a range of different expertise are caring for them. There is also a problem because patients who complain about the way they are treated face a group rather than one individual opposing them.[9]

Vienna's NarrenturmGerman for "fools' tower" — was one of the earliest buildings specifically designed as a "madhouse". It was built in 1784.

Since the 1960s there have been many challenges to the concept of mental illness itself. Thomas Szasz wrote The Myth of Mental Illness (1960) which said that mental illnesses are not real in the sense that cancers are real. Except for a few identifiable brain diseases, such as Alzheimer’s disease, there are "neither biological or chemical tests nor biopsy or necropsy findings" for verifying or falsifying psychiatric diagnoses. There are no objective methods for detecting the presence or absence of mental disease. Szasz argued that mental illness was a myth used to disguise moral conflicts. He has said "serious persons ought not to take psychiatry seriously -- except as a threat to reason, responsibility and liberty".[10]

Sociologists such as Erving Goffman and Thomas Scheff said that mental illness was merely another example of how society labels and controls non-conformists; behavioural psychologists challenged psychiatry's fundamental reliance on unobservable phenomena; and gay rights activists criticised the APA's listing of homosexuality as a mental disorder. A widely publicised study by Rosenhan in Science was viewed as an attack on the efficacy of psychiatric diagnosis.[11]

These critiques targeted the heart of psychiatry:

They suggested that psychiatry's core concepts were myths, that psychiatry's relationship to medical science had only historical connections, that psychiatry was more aptly characterised as a vast system of coercive social management, and that its paradigmatic practice methods (the talking cure and psychiatric confinement) were ineffective or worse.[12]:136

Medicalization

Conversation between doctor and patient/consumer.

For many years, some psychiatrists (such as David Rosenhan, Peter Breggin, Paula Caplan, Thomas Szasz) and outside critics (such as Stuart A. Kirk) have "been accusing psychiatry of engaging in the systematic medicalization of normality". More recently these concerns have come from insiders who have worked for and promoted the APA (e.g., Robert Spitzer, Allen Frances).[12]:185 In 2013, Allen Frances said that "psychiatric diagnosis still relies exclusively on fallible subjective judgments rather than objective biological tests".[2][3]

Medicalization (or medicalisation) is the process by which human conditions and problems come to be defined and treated as medical conditions, and thus become the subject of medical study, diagnosis, prevention, or treatment. Medicalization can be driven by new evidence or hypotheses about conditions; by changing social attitudes or economic considerations; or by the development of new medications or treatments.

The concept of medicalization was devised by sociologists to explain how medical knowledge is applied to behaviors which are not self-evidently medical or biological.[13] The term medicalization entered the sociology literature in the 1970s in the works of Irving Zola, Peter Conrad and Thomas Szasz, among others. These sociologists viewed medicalization as a form of social control in which medical authority expanded into domains of everyday existence, and they rejected medicalization in the name of liberation. This critique was embodied in works such as Conrad's "The discovery of hyperkinesis: notes on medicalization of deviance", published in 1973 (hyperkinesis was the term then used to describe what we might now call ADHD).[14] Nevertheless, opium was used to pacify children in ancient Egypt before 2000 BC.

These sociologists did not believe medicalization to be a new phenomenon, arguing that medical authorities had always been concerned with social behavior and traditionally functioned as agents of social control (Foucault, 1965; Szasz,1970; Rosen). However, these authors took the view that increasingly sophisticated technology had extended the potential reach of medicalization as a form of social control, especially in terms of "psychotechnology" (Chorover,1973).

In the 1975 book Limits to medicine: Medical nemesis (1975), Ivan Illich put forth one of the earliest uses of the term "medicalization". Illich, a philosopher, argued that the medical profession harms people through iatrogenesis, a process in which illness and social problems increase due to medical intervention. Illich saw iatrogenesis occurring on three levels: the clinical, involving serious side effects worse than the original condition; the social, whereby the general public is made docile and reliant on the medical profession to cope with life in their society; and the structural, whereby the idea of aging and dying as medical illnesses effectively "medicalized" human life and left individuals and societies less able to deal with these "natural" processes.

Marxists such as Vicente Navarro (1980) linked medicalization to an oppressive capitalist society. They argued that medicine disguised the underlying causes of disease, such as social inequality and poverty, and instead presented health as an individual issue. Others[15] examined the power and prestige of the medical profession, including use of terminology to mystify and of professional rules to exclude or subordinate others.

Some argue that in practice the process of medicalization tends to strip subjects of their social context, so they come to be understood in terms of the prevailing biomedical ideology, resulting in a disregard for overarching social causes such as unequal distribution of power and resources.[16] A series of publications by Mens Sana Monographs have focused on medicine as a corporate capitalist enterprise.[17][18][19]

Political abuse

Psychiatrists have been involved in human rights abuses in states across the world when the definitions of mental disease were expanded to include political disobedience.[20] As scholars have long argued, governmental and medical institutions code menaces to authority as mental diseases during political disturbances. Nowadays, in many countries, political prisoners are sometimes confined and abused in mental institutions.[21]:3 Psychiatric confinement of sane people is a particularly pernicious form of repression.[22]

Psychiatry possesses a built-in capacity for abuse that is greater than in other areas of medicine.[23] The diagnosis of mental disease allows the state to hold persons against their will and insist upon therapy in their interest and in the broader interests of society.[23] In addition, receiving a psychiatric diagnosis can in itself be regarded as oppressive.[24]:94 In a monolithic state, psychiatry can be used to bypass standard legal procedures for establishing guilt or innocence and allow political incarceration without the ordinary odium attaching to such political trials.[23] The use of hospitals instead of jails prevents the victims from receiving legal aid before the courts, makes indefinite incarceration possible, discredits the individuals and their ideas.[25]:29 In that manner, whenever open trials are undesirable, they are avoided.[25]:29

Examples of political abuse of the power, entrusted in physicians and particularly psychiatrists, are abundant in history and seen during the Nazi era and the Soviet rule when political dissenters were labeled as “mentally ill” and subjected to inhumane “treatments.”[26] In the period from the 1960s up to 1986, abuse of psychiatry for political purposes was reported to be systematic in the Soviet Union, and occasional in other Eastern European countries such as Romania, Hungary, Czechoslovakia, and Yugoslavia.[23] The practice of incarceration of political dissidents in mental hospitals in Eastern Europe and the former USSR damaged the credibility of psychiatric practice in these states and entailed strong condemnation from the international community.[27] Political abuse of psychiatry also takes place in the People's Republic of China[28] and in Russia.[29] Psychiatric diagnoses such as the diagnosis of ‘sluggish schizophrenia’ in political dissidents in the USSR were used for political purposes.[30]:77

Electroconvulsive therapy

Electroconvulsive therapy (ECT) was one treatment that the anti-psychiatry movement wanted eliminated.[31] Their arguments were that ECT damages the brain,[31] and was used as punishment or as a threat to keep the patients "in line".[31] Since then, ECT has improved considerably,[32] and is performed under general anaesthetic in a medically supervised environment.[33]

The National Institute for Health and Care Excellence recommends ECT for the short term treatment of severe, treatment-resistant depression, and advises against its use in schizophrenia.[34][35] According to the Canadian Network for Mood and Anxiety Treatments, ECT is more efficacious for the treatment of depression than antidepressants, with a response rate of 90% in first line treatment and 50-60% in treatment-resistant patients.[36] On the other hand, a 2010 literature review concluded that ECT had minimal benefits for people with depression and schizophrenia.[37]

The most common side effects include headache, muscle soreness, confusion, and temporary loss of recent memory.[33][38] There is strong evidences that ECT causes structural brain damages, observable on MRI.[39] Before these advanced brain imaging techniques, some researchers said that ECT doesn't cause physical damage.[36] The observation on MRI of objective lesions in the brain is consistent with research on cognitive impairments.[40]

Marketing of antipsychotic drugs

Psychiatry has greatly benefitted by advances in pharmacotherapy.[1]:110–112[41] However, the close relationship between those prescribing psychiatric medication and pharmaceutical companies, and the risk of a conflict of interest,[41] is also a source of concern. This marketing by the pharmaceutical industry has an influence on practicing psychiatrists, which affects prescription.[41] Child psychiatry is one of the areas in which prescription has grown massively. In the past, it was rare, but nowadays child psychiatrists on a regular basis prescribe psychotropic drugs for children, for instance Ritalin.[1]:110–112

Joanna Moncrieff has argued that antipsychotic drug treatment is often undertaken as a means of control rather than to treat specific symptoms experienced by the patient.[42] Moncreiff has further argued that the evidence for antipsychotics from discontinuation-relapse studies may be flawed, because they do not take into account that antipsychotics may sensitize the brain and provoke psychosis if discontinued, which may then be wrongly interpreted as a relapse of the original condition.[43]

Use of this class of drugs has a history of criticism in residential care. As the drugs used can make patients calmer and more compliant, critics claim that the drugs can be overused. Outside doctors can feel under pressure from care home staff.[44] In an official review commissioned by UK government ministers it was reported that the needless use of antipsychotic medication in dementia care was widespread and was linked to 1800 deaths per year.[45][46] In the US, the government has initiated legal action against the pharmaceutical company Johnson & Johnson for allegedly paying kickbacks to Omnicare to promote its antipsychotic risperidone (Risperdal) in nursing homes.[47]

There has also been controversy about the role of pharmaceutical companies in marketing and promoting antipsychotics, including allegations of downplaying or covering up adverse effects, expanding the number of conditions or illegally promoting off-label usage; influencing drug trials (or their publication) to try to show that the expensive and profitable newer atypicals were superior to the older cheaper typicals that were out of patent. Following charges of illegal marketing, settlements by two large pharmaceutical companies in the US set records for the largest criminal fines ever imposed on corporations.[48] One case involved Eli Lilly and Company's antipsychotic Zyprexa, and the other involved Bextra. In the Bextra case, the government also charged Pfizer with illegally marketing another antipsychotic, Geodon.[48] In addition, Astrazeneca faces numerous personal-injury lawsuits from former users of Seroquel (quetiapine), amidst federal investigations of its marketing practices.[49] By expanding the conditions for which they were indicated, Astrazeneca's Seroquel and Eli Lilly's Zyprexa had become the biggest selling antipsychotics in 2008 with global sales of $5.5 billion and $5.4 billion respectively.[50]

Harvard medical professor Joseph Biederman conducted research on bipolar disorder in children that led to an increase in such diagnoses. A 2008 Senate investigation found that Biederman also received $1.6 million in speaking and consulting fees between 2000 and 2007 — some of them undisclosed to Harvard — from companies including makers of antipsychotic drugs prescribed for children with bipolar disorder. Johnson & Johnson gave more than $700,000 to a research center that was headed by Biederman from 2002 to 2005, where research was conducted, in part, on Risperdal, the company's antipsychotic drug. Biederman has responded saying that the money did not influence him and that he did not promote a specific diagnosis or treatment.[48]

In 2004, University of Minnesota research participant Dan Markingson committed suicide while enrolled in an industry-sponsored pharmaceutical trial comparing three FDA-approved atypical antipsychotics: Seroquel (quetiapine), Zyprexa (olanzapine), and Risperdal (risperidone). Writing on the circumstances surrounding Markingson's death in the study, which was designed and funded by Seroquel manufacturer AstraZeneca, University of Minnesota Professor of Bioethics Carl Elliott noted that Markingson was enrolled in the study against the wishes of his mother, Mary Weiss, and that he was forced to choose between enrolling in the study or being involuntarily committed to a state mental institution.[51] Further investigation revealed financial ties to AstraZeneca by Markingson's psychiatrist, Dr. Stephen C. Olson, oversights and biases in AstraZeneca's trial design, and the inadequacy of university Institutional Review Board (IRB) protections for research subjects.[52] A 2005 FDA investigation cleared the university. Nonetheless, controversy around the case has continued. Mother Jones resulted in a group of university faculty members sending a public letter to the university Board of Regents urging an external investigation into Markingson's death.[53]

Pharmaceutical companies have also been accused of attempting to set the mental health agenda through activities such as funding consumer advocacy groups.[54]

In an effort to reduce the potential for hidden conflicts of interest between researchers and pharmaceutical companies, the US Government issued a mandate in 2012 requiring that drug manufacturers receiving funds under the Medicare and Medicaid programs collect data, and make public, all gifts to doctors and hospitals.[12]:317

Prisoner experimentation

Prisoners in psychiatric hospitals have been the subjects of experiments involving new medications. Vladimir Khailo of the USSR was an individual exposed to such treatment in the 1980s.[55] However, the involuntary treatment of prisoners by use of psychiatric drugs has not been limited to Khailo, nor the USSR.

ADHD

ADHD, its diagnosis, and its treatment have been controversial since the 1970s.[56][57][58] The controversies involve clinicians, teachers, policymakers, parents, and the media. Positions range from the view that ADHD is within the normal range of behavior[59][60] to the hypothesis that ADHD is a genetic condition.[61] Other areas of controversy include the use of stimulant medications in children,[57][62] the method of diagnosis, and the possibility of overdiagnosis.[62] In 2012, the National Institute for Health and Care Excellence, while acknowledging the controversy, states that the current treatments and methods of diagnosis are based on the dominant view of the academic literature.[59] In 2014, Keith Conners, one of the early advocates for recognition of the disorder, spoke out against overdiagnosis in a New York Times article.[63] In contrast, a 2014 peer-reviewed medical literature review indicated that ADHD is underdiagnosed in adults.[64]

With widely differing rates of diagnosis across countries, states within countries, races, and ethnicities, some suspect factors other than the presence of the symptoms of ADHD are playing a role in diagnosis.[65] Some sociologists consider ADHD to be an example of the medicalization of deviant behavior, that is, the turning of the previously non-medical issue of school performance into a medical one.[56][66] Most healthcare providers accept ADHD as a genuine disorder, at least in the small number of people with severe symptoms.[66] Among healthcare providers the debate mainly centers on diagnosis and treatment in the much larger number of people with less severe symptoms.[66][67][68]

As of 2009, 8% of all United States Major League Baseball players had been diagnosed with ADHD, making the disorder common among this population. The increase coincided with the League's 2006 ban on stimulants, which has raised concern that some players are mimicking or falsifying the symptoms or history of ADHD to get around the ban on the use of stimulants in sport.[69]

Schizophrenia diagnosis

Underlying issues associated with schizophrenia would be better addressed as a spectrum of conditions[70] or as individual dimensions along which everyone varies rather than by a diagnostic category based on an arbitrary cut-off between normal and ill.[71] This approach appears consistent with research on schizotypy, and with a relatively high prevalence of psychotic experiences, mostly non-distressing delusional beliefs, among the general public.[72][73][74] In concordance with this observation, psychologist Edgar Jones, and psychiatrists Tony David and Nassir Ghaemi, surveying the existing literature on delusions, pointed out that the consistency and completeness of the definition of delusion have been found wanting by many; delusions are neither necessarily fixed nor false, and need not involve the presence of incontrovertible evidence.[75][76][77]

Nancy Andreasen has criticized the current DSM-IV and ICD-10 criteria for sacrificing diagnostic validity for the sake of artificially improving reliability. She argues that overemphasis on psychosis in the diagnostic criteria, while improving diagnostic reliability, ignores more fundamental cognitive impairments that are harder to assess due to large variations in presentation.[78][79] This view is supported by other psychiatrists.[80] In the same vein, Ming Tsuang and colleagues argue that psychotic symptoms may be a common end-state in a variety of disorders, including schizophrenia, rather than a reflection of the specific etiology of schizophrenia, and warn that there is little basis for regarding DSM’s operational definition as the "true" construct of schizophrenia.[70] Neuropsychologist Michael Foster Green went further in suggesting the presence of specific neurocognitive deficits may be used to construct phenotypes that are alternatives to those that are purely symptom-based. These deficits take the form of a reduction or impairment in basic psychological functions such as memory, attention, executive function and problem solving.[81][82]

The exclusion of affective components from the criteria for schizophrenia, despite their ubiquity in clinical settings, has also caused contention. This exclusion in the DSM has resulted in a "rather convoluted" separate disorder—schizoaffective disorder.[80] Citing poor interrater reliability, some psychiatrists have totally contested the concept of schizoaffective disorder as a separate entity.[83][84] The categorical distinction between mood disorders and schizophrenia, known as the Kraepelinian dichotomy, has also been challenged by data from genetic epidemiology.[85]

Deep Sleep Therapy

Controversial Australian psychiatrist Harry Bailey treated mental patients via deep sleep therapy and other methods at Chelmsford Private Hospital, a Sydney mental hospital. He has been linked with the deaths of 85 patients, including 19 who committed suicide.[86]

The resultant scandal broke in the early 1980s, following two 60 Minutes programs in 1980 and 1982, and closed down Chelmsford entirely. In 1985, the "legal and medical investigative machinery finally co-ordinated their actions and Bailey was facing committal proceedings over the death of Miriam Podio in 1977".[87] The Chelmsford Royal Commission under the Greiner government from 1988 to 1990, headed by Justice John Slattery of the New South Wales Supreme Court, produced findings concerning Chelmsford's treatment program that ran to twelve volumes and described deplorable conditions, fraud, and misconduct and medical negligence. Bailey committed suicide by ingesting barbiturates at Mount White.

Anti-psychiatry

Main article: Anti-psychiatry

Controversy has often surrounded psychiatry,[1] and the anti-psychiatry message is that psychiatric treatments are ultimately more damaging than helpful to patients. Psychiatry is often thought to be a benign medical practice, but at times is seen by some as a coercive instrument of oppression. Psychiatry is seen to involve an unequal power relationship between doctor and patient, and advocates of anti-psychiatry claim a subjective diagnostic process, leaving much room for opinions and interpretations.[1][4] Every society, including liberal Western society, permits compulsory treatment of mental patients.[1] The World Health Organization (WHO) recognizes that "poor quality services and human rights violations in mental health and social care facilities are still an everyday occurrence in many places", but has recently taken steps to improve the situation globally.[88]

Psychiatry's history involves what some view as dangerous treatments.[1] Electroconvulsive therapy is one of these, which was used widely between the 1930s and 1960s and is still in use today. The brain surgery procedure lobotomy is another practice that was ultimately seen as too invasive and brutal.[4] In the US, between 1939 and 1951, over 50,000 lobotomy operations were performed in mental hospitals. Valium and other sedatives have arguably been over-prescribed, leading to a claimed epidemic of dependence. Concerns also exist for the significant increase in prescription of psychiatric drugs to children.[1][4]

Three authors have come to personify the movement against psychiatry, of which two are or have been practicing psychiatrists. The most influential was R.D. Laing, who wrote a series of best-selling books, including; The Divided Self. Thomas Szasz rose to fame with the book The Myth of Mental Illness. Michael Foucault challenged the very basis of psychiatric practice and cast it as repressive and controlling. The term "anti-psychiatry" itself was coined by David Cooper in 1967.[1][4]

Divergence within psychiatry generated the anti-psychiatry movement in the 1960s and 1970s, and is still present. Issues remaining relevant in contemporary psychiatry are questions of; freedom versus coercion, mind versus brain, nature versus nurture, and the right to be different.[1]

Psychiatric survivors movement

The psychiatric survivors movement[89] arose out of the civil rights ferment of the late 1960s and early 1970s and the personal histories of psychiatric abuse experienced by some ex-patients rather than the intradisciplinary discourse of antipsychiatry.[90] The key text in the intellectual development of the survivor movement, at least in the USA, was Judi Chamberlin's 1978 text, On Our Own: Patient Controlled Alternatives to the Mental Health System.[89][91] Chamberlin was an ex-patient and co-founder of the Mental Patients' Liberation Front.[92] Coalescing around the ex-patient newsletter Dendron,[93] in late 1988 leaders from several of the main national and grassroots psychiatric survivor groups felt that an independent, human rights coalition focused on problems in the mental health system was needed. That year the Support Coalition International (SCI) was formed. SCI's first public action was to stage a counter-conference and protest in New York City, in May, 1990, at the same time as (and directly outside of) the American Psychiatric Association's annual meeting.[94] In 2005 the SCI changed its name to Mind Freedom International with David W. Oaks as its director.[90]

References

  1. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Burns, Tom (2006). Psychiatry: A very short introduction. Oxford University Press. ISBN 9780192807274.
  2. 1 2 Frances A (6 August 2013). "The new crisis of confidence in psychiatric diagnosis". Annals of Internal Medicine. 159 (2): 221–222. doi:10.7326/0003-4819-159-3-201308060-00655. PMID 23685989.
  3. 1 2 Frances A (January 2013). "The past, present and future of psychiatric diagnosis". World Psychiatry. 12 (2): 111–112. doi:10.1002/wps.20027. PMC 3683254Freely accessible. PMID 23737411.
  4. 1 2 3 4 5 6 Nasrallah, Henry A. (December 2011). "The antipsychiatry movement: Who and why" (PDF). Current Psychiatry. 10 (12): 4, 6, 53.
  5. "New mental health rights proposed by minister Norman Lamb". BBC News. 6 March 2015.
  6. Henderson, Saras (July 2003). "Power imbalance between nurses and patients: a potential inhibitor of partnership in care". Journal of Clinical Nursing. 12 (4): 501–508. doi:10.1046/j.1365-2702.2003.00757.x.
  7. Kumar, S (2000). "Client empowerment in psychiatry and the professional abuse of clients: where do we stand". International Journal of Psychiatry in Medicine. 30 (1): 61–70. doi:10.2190/AC9N-YTLE-B639-M3P4. PMID 10900561.
  8. Taylor, Hannah (15 February 2013). "Values in Everyday Mental Health Nursing: Power and Partnership" (PDF).
  9. Pols, Jan (2005) [1984], "The Psychiatrist-Patient Relationship", The Politics of Mental Illness: Myth and Power in the Work of Thomas S. Szasz, Translated by Mira de Vries, ISBN 978-90-805136-4-8, OCLC 520590308
  10. Szasz, Thomas (2008). Psychiatry:The Science of Lies. Syracuse, NY: Syracuse University Press. pp. 25, 117. ISBN 978-0-8156-0910-0. OCLC 225870841.
  11. Kirk, Stuart A.; Kutchins, Herb (1994). "The Myth of the Reliability of DSM". Journal of Mind and Behavior. 15 (1&2): 71–86. Archived from the original on 2008-03-07. Reprinted by Academy for the Study of the Psychoanalytic Arts.
  12. 1 2 3 Kirk, Stuart A. (2013). Mad Science: Psychiatric Coercion, Diagnosis, and Drugs. Transaction Publishers.
  13. White, Kevin (2002). An introduction to the sociology of health and illness. SAGE. p. 42. ISBN 0-7619-6400-2.
  14. Conrad P (October 1975). "The discovery of hyperkinesis: notes on the medicalization of deviant behavior". Soc Probl. 23 (1): 1221. doi:10.1525/sp.1975.23.1.03a00020. PMID 11662312.
  15. Helman, Cecil (2007). Culture, Health and Illness. London: Arnold. ISBN 9780340914502.
  16. Filc D (September 2004). "The medical text: between biomedicine and hegemony". Soc Sci Med. 59 (6): 1275–85. doi:10.1016/j.socscimed.2004.01.003. PMID 15210098.
  17. Ajai R Singh, Shakuntala A Singh, 2005, "Medicine as a corporate enterprise, patient welfare centered profession, or patient welfare centered professional enterprise?" Mens Sana Monographs, 3(2), p19-51
  18. Ajai R Singh, Shakuntala A Singh, 2005, "The connection between academia and industry", Mens Sana Monographs, 3(1), p5-35
  19. Ajai R Singh, Shakuntala A Singh, 2005, "Public welfare agenda or corporate research agenda?", Mens Sana Monographs, 3(1), p41-80.
  20. Semple, David; Smyth, Roger; Burns, Jonathan (2005). Oxford handbook of psychiatry. Oxford: Oxford University Press. p. 6. ISBN 0-19-852783-7.
  21. Noll, Richard (2007). The encyclopedia of schizophrenia and other psychotic disorders. Infobase Publishing. p. 3. ISBN 0-8160-6405-9.
  22. Bonnie, Richard (2002). "Political Abuse of Psychiatry in the Soviet Union and in China: Complexities and Controversies" (PDF). Journal of the American Academy of Psychiatry and the Law. 30 (1): 136–144. PMID 11931362. Retrieved 12 December 2010.
  23. 1 2 3 4 British Medical Association (1992). Medicine betrayed: the participation of doctors in human rights abuses. Zed Books. p. 65-66. ISBN 1-85649-104-8.
  24. Malterud, Kirsti; Hunskaar, Steinar (2002). Chronic myofascial pain: a patient-centered approach. Radcliffe Publishing. p. 94. ISBN 1-85775-947-8.
  25. 1 2 Veenhoven, Willem; Ewing, Winifred; Samenlevingen, Stichting (1975). Case studies on human rights and fundamental freedoms: a world survey. Martinus Nijhoff Publishers. p. 29. ISBN 90-247-1780-9.
  26. Shah R, Basu D (July–September 2010). "Coercion in psychiatric care: Global and Indian perspective". Indian Journal of Psychiatry. 52 (3): 203–206. doi:10.4103/0019-5545.70971. PMC 2990818Freely accessible. PMID 21180403.
  27. Declan, Lyons; Art, O'Malley (1 December 2002). "The labelling of dissent — politics and psychiatry behind the Great Wall". Psychiatriс Bulletin. 26 (12): 443–444. doi:10.1192/pb.26.12.443.
  28. Voren, Robert van (January 2010). "Political Abuse of Psychiatry—An Historical Overview". Schizophrenia Bulletin. 36 (1): 33–35. doi:10.1093/schbul/sbp119. PMC 2800147Freely accessible. PMID 19892821.
  29. Voren, Robert van (2013). Psychiatry as a tool of coercion in post-Soviet countries (PDF). The European Parliament. doi:10.2861/28281. ISBN 978-92-823-4595-5.
  30. Katona, Cornelius; Robertson, Mary (2005). Psychiatry at a glance. Wiley-Blackwell. p. 77. ISBN 1-4051-2404-0.
  31. 1 2 3 Shorter 1997, p. 282.
  32. Hales, E; Yudofsky, JA, eds. (2003), The American Psychiatric Press Textbook of Psychiatry (4th ed.), Washington, DC: American Psychiatric Publishing, p. 444, ISBN 9781585620326, OCLC 49576699
  33. 1 2 Fink, M; Taylor, MA (18 July 2007). "Electroconvulsive therapy: evidence and challenges". JAMA. 298 (3): 330–2. doi:10.1001/jama.298.3.330. PMID 17635894.
  34. "Guidance", Depression in adults: The treatment and management of depression in adults, London, UK: National Institute for Health and Care Excellence, October 2009
  35. The use of electroconvulsive therapy: Understanding NICE guidance – information for service users, their advocates and carers, and the public (PDF), London, UK: National Institute for Health and Care Excellence, April 2003, ISBN 978-1-84257-284-9
  36. 1 2 Kennedy, SH; Milev, R; Giacobbe, P; Ramasubbu, R; Lam, RW; Parikh, SV; Patten, SB; Ravindran, AV (October 2009). "Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. IV. Neurostimulation therapies". J Affect Disord. 117 (Suppl 1): S44–53. doi:10.1016/j.jad.2009.06.039. PMID 19656575.
  37. Read, J; Bentall, R (Oct–Dec 2010). "The effectiveness of electroconvulsive therapy: a literature review" (PDF). Epidemiologia e psichiatria sociale. 19 (4): 333–47. doi:10.1017/S1121189X00000671. PMID 21322506.
  38. Rose, D; Fleischmann, P; Wykes, T; Leese, M; Bindman, J (21 June 2003). "Patients' perspectives on electroconvulsive therapy: systematic review". BMJ. 326 (7403): 1363. doi:10.1136/bmj.326.7403.1363. PMC 162130Freely accessible. PMID 12816822.
  39. Jennifer S. Perrin and all (2012) Electroconvulsive therapy reduces frontal cortical connectivity in severe depressive disorder
  40. Sackeim et al. (2007) The cognitive effects of electroconvulsive therapy in community settings
  41. 1 2 3 "The Relationship between Psychiatrists, College of Psychiatrists of Ireland and the Pharmaceutical Industry: Position Paper EAP04/2013" (PDF). College of Psychiatrists of Ireland. December 2012. Retrieved 2013-04-22.
  42. James, Adam (2 March 2008). "Myth of the antipsychotic". The Guardian. Guardian News and Media Limited. Retrieved 27 July 2012.
  43. Moncrieff J (2006). "Why is it so difficult to stop psychiatric drug treatment? It may be nothing to do with the original problem". Med. Hypotheses. 67 (3): 517–23. doi:10.1016/j.mehy.2006.03.009. PMID 16632226.
  44. GPs under 'pressure' to issue neuroleptics, claims professor, Chemist + Druggist, 15 January 2009
  45. Nick Triggle (12 November 2009). "Dementia drug use 'killing many'". BBC. Retrieved 2013-05-07.
  46. "UK study warns against antipsychotics for dementia". reuters. Nov 12, 2009. Retrieved 2013-05-07.
  47. Hilzenrath, David S. (16 January 2010). "Justice suit accuses Johnson & Johnson of paying kickbacks". The Washington Post. Retrieved 17 January 2010.
  48. 1 2 3 Wilson, Duff (October 2, 2010). "Side Effects May Include Lawsuits". New York Times.
  49. DUFF WILSON (27 February 2009). "Drug Maker's E-Mail Released in Seroquel Lawsuit". The New York Times. The New York Times Company. Retrieved 27 July 2012.
  50. Pipelineantipsychotic drugs to drive next market evolution (2009). Healthcarefinancenews.com (7 August 2009).
  51. Elliott, Carl (September/October 2010). "The deadly corruption of clinical trials." Mother Jones: http://www.motherjones.com/environment/2010/09/dan-markingson-drug-trial-astrazeneca
  52. Carl. "Dan Markingson Investigation". Retrieved February 14, 2016.
  53. "U of M Board of Regents Markingson Letter". Scribd. Retrieved February 14, 2016.
  54. Gosden R, Beder S (2001). "Pharmaceutical industry agenda setting in mental health policies". Ethical Human Sciences and Services : an International Journal of Critical Inquiry. 3 (3): 147–59. PMID 15278977.
  55. Andreyev, Galina (2012). Subjected to Intense Persecution. Xulon Press. p. 194. ISBN 1622304063.
  56. 1 2 Parrillo, VN (2008), Encyclopedia of Social Problems, Volume 1, SAGE, p. 63, ISBN 9781412941655, retrieved 7 Apr 2016
  57. 1 2 Sim MG, Hulse G, Khong E (August 2004). "When the child with ADHD grows up". Australian Family Physician. 33 (8): 615–8. PMID 15373378.
  58. Foreman DM (February 2006). "Attention deficit hyperactivity disorder: legal and ethical aspects". Archives of Disease in Childhood. 91 (2): 192–194. doi:10.1136/adc.2004.064576. PMC 2082674Freely accessible. PMID 16428370.
  59. 1 2 National Collaborating Centre for Mental Health (2009), Attention Deficit Hyperactivity Disorder: Diagnosis and Management of ADHD in Children, Young People and Adults, British Psychological Society, pp. 19–27, 38, 130, 133, 317, ISBN 9781854334718
  60. Faraone, Stephen V (2005). "The scientific foundation for understanding attention-deficit/hyperactivity disorder as a valid psychiatric disorder". Eur Child Adolesc Psychiatry. 14 (1): 1–10. doi:10.1007/s00787-005-0429-z. PMID 15756510.
  61. Boseley, Sarah (30 September 2010). "Hyperactive children may suffer from genetic disorder, says study". The Guardian.
  62. 1 2 Cormier E (October 2008). "Attention deficit/hyperactivity disorder: a review and update". J Pediatr Nurs. 23 (5): 345–357. doi:10.1016/j.pedn.2008.01.003. PMID 18804015.
  63. Schwarz, Alan (14 December 2013). "The Selling of Attention Deficit Disorder" (14 December 2013). The New York Times. Retrieved 26 February 2015.
  64. Ginsberg Y, Quintero J, Anand E, Casillas M, Upadhyaya HP (2014). "Underdiagnosis of attention-deficit/hyperactivity disorder in adult patients: a review of the literature". Prim Care Companion CNS Disord. 16 (3). doi:10.4088/PCC.13r01600. PMC 4195639Freely accessible. PMID 25317367. Reports indicate that ADHD affects 2.5%–5% of adults in the general population,5–8 compared with 5%–7% of children.9,10 ... However, fewer than 20% of adults with ADHD are currently diagnosed and/or treated by psychiatrists.7,15,16
  65. Elder TE (September 2010). "The importance of relative standards in ADHD diagnoses: evidence based on exact birth dates". J Health Econ. 29 (5): 641–656. doi:10.1016/j.jhealeco.2010.06.003. PMC 2933294Freely accessible. PMID 20638739.
  66. 1 2 3 Mayes R, Bagwell C, Erkulwater JL (2009). Medicating Children: ADHD and Pediatric Mental Health (illustrated ed.). Harvard University Press. pp. 4–24. ISBN 9780674031630.
  67. Silver LB (2004). Attention-deficit/hyperactivity disorder (3rd ed.). American Psychiatric Publishing. pp. 4–7. ISBN 9781585621316.
  68. Schonwald A, Lechner E (April 2006). "Attention deficit/hyperactivity disorder: complexities and controversies". Curr. Opin. Pediatr. 18 (2): 189–195. doi:10.1097/01.mop.0000193302.70882.70. PMID 16601502.
  69. Saletan, William (12 January 2009). "Doping Deficit Disorder. Need performance-enhancing drugs? Claim ADHD". Slate. Archived from the original on 21 May 2009. Retrieved 2 May 2009.
  70. 1 2 Tsuang MT, Stone WS, Faraone SV. Toward reformulating the diagnosis of schizophrenia. American Journal of Psychiatry. 2000;157(7):1041–50. doi:10.1176/appi.ajp.157.7.1041. PMID 10873908.
  71. Peralta V, Cuesta MJ. A dimensional and categorical architecture for the classification of psychotic disorders. World Psychiatry. 2007;6(2):100–1. PMID 18235866.
  72. Verdoux H, van Os J. Psychotic symptoms in non-clinical populations and the continuum of psychosis. Schizophrenia Research. 2002;54(1–2):59–65. doi:10.1016/S0920-9964(01)00352-8. PMID 11853979.
  73. Johns LC, van Os J. The continuity of psychotic experiences in the general population. Clinical Psychology Review. 2001;21(8):1125–41. doi:10.1016/S0272-7358(01)00103-9. PMID 11702510.
  74. Peters ER, Day S, McKenna J, Orbach G. Measuring delusional ideation: the 21-item Peters et al. Delusions Inventory (PDI). Schizophrenia Bulletin. 2005;30(4):1005–22. doi:10.1093/oxfordjournals.schbul.a007116. PMID 15954204.
  75. Jones E. The Phenomenology of Abnormal Belief: A Philosophical and Psychiatric Inquiry. Philosophy, Psychiatry and Psychology. 1999;6(1):1–16.
  76. David AS. On the impossibility of defining delusions. Philosophy, Psychiatry and Psychology. 1999 [Retrieved 2008-02-24];6(1):17–20.
  77. Ghaemi SN. An Empirical Approach to Understanding Delusions. Philosophy, Psychiatry and Psychology. 1999 [Retrieved 2008-02-24];6(1):21–24.
  78. Andreasen NC. Schizophrenia: the fundamental questions. Brain Res. Brain Res. Rev.. 2000;31(2–3):106–12. doi:10.1016/S0165-0173(99)00027-2. PMID 10719138.
  79. Andreasen NC. A unitary model of schizophrenia: Bleuler's "fragmented phrene" as schizencephaly. Archives of General Psychiatry. 1999;56(9):781–7. doi:10.1001/archpsyc.56.9.781. PMID 12884883.
  80. 1 2 Jansson LB, Parnas J. Competing definitions of schizophrenia: what can be learned from polydiagnostic studies?. Schizophr Bull. 2007;33(5):1178–200. doi:10.1093/schbul/sbl065. PMID 17158508. PMC 3304082.
  81. Green MF, Nuechterlein KH. Should schizophrenia be treated as a neurocognitive disorder?. Schizophr Bull. 1999;25(2):309–19. PMID 10416733.
  82. Green, Michael. Schizophrenia revealed: from neurons to social interactions. New York: W.W. Norton; 2001. ISBN 0-393-70334-7. Lay summary: NEJM book review.
  83. Lake CR, Hurwitz N. Schizoaffective disorder merges schizophrenia and bipolar disorders as one disease—there is no schizoaffective disorder. Curr Opin Psychiatry. 2007;20(4):365–79. doi:10.1097/YCO.0b013e3281a305ab. PMID 17551352.
  84. Malhi GS, Green M, Fagiolini A, Peselow ED, Kumari V. Schizoaffective disorder: diagnostic issues and future recommendations. Bipolar Disorders. 2008;10(1 Pt 2):215–30. doi:10.1111/j.1399-5618.2007.00564.x. PMID 18199238.
  85. Craddock N, Owen MJ. The beginning of the end for the Kraepelinian dichotomy. Br J Psychiatry. 2005;186:364–6. doi:10.1192/bjp.186.5.364. PMID 15863738.
  86. Kaplan, Robert (2009). Medical Murder: Disturbing Cases of Doctors Who Kill. Allen & Unwin. ISBN 1741765773.
  87. Malcolm Knox (April 13, 2013). "The big sleep". The Age. Archived from the original on 2014-03-06.
  88. "WHO gives countries tools to help stop abuse of people with mental health conditions". WHO. Retrieved 12 June 2014.
  89. 1 2 Corrigan, Patrick W.; David Roe; Hector W. H. Tsang (2011-05-23). Challenging the Stigma of Mental Illness: Lessons for Therapists and Advocates. John Wiley and Sons. ISBN 978-1-119-99612-5.
  90. 1 2 Oaks D (2006-08-01). "The evolution of the consumer movement". Psychiatric Services. 57 (8): 1212. doi:10.1176/appi.ps.57.8.1212 (inactive 2015-03-27). PMID 16870979. Retrieved 2011-08-05.
  91. Chamberlin, Judi (1978). On Our Own: Patient-Controlled Alternatives to the Mental Health System. New York: Hawthorne. ISBN 080155523X.
  92. Rissmiller DJ, Rissmiller JH (2006-06-01). "Evolution of the antipsychiatry movement into mental health consumerism". Psychiatric Services. 57 (6): 863–6 [865]. doi:10.1176/appi.ps.57.6.863 (inactive 2015-03-27). PMID 16754765. Retrieved 2011-08-05.
  93. Ludwig, Gregory (2006-08-01). "Letter". Psychiatric Services. 57 (8): 1213. doi:10.1176/appi.ps.57.8.1213 (inactive 2015-03-27). PMID 16870981. Retrieved 2011-08-05.
  94. About Us — MFI Portal
Cited texts
  • Gask, L (2004), A Short Introduction to Psychiatry, London: SAGE Publications Ltd., ISBN 978-0-7619-7138-2 
  • Guze, SB (1992), Why Psychiatry Is a Branch of Medicine, New York: Oxford University Press, ISBN 978-0-19-507420-8 
  • Lyness, JM (1997), Psychiatric Pearls, Philadelphia: F.A. Davis Company, ISBN 978-0-8036-0280-9 
  • Shorter, E (1997), A History of Psychiatry: From the Era of the Asylum to the Age of Prozac, New York: John Wiley & Sons, Inc., ISBN 978-0-471-24531-5 
This article is issued from Wikipedia - version of the 11/30/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.